Fore Bio is a next-generation precision oncology company that utilizes its functional genomics platform to hyper-target therapies to unaddressed tumor mutations, providing patients with few therapeutic alternatives with new treatments tailored to them.

Matthew Ros

Fore Bio

We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics. Deeply rooted in science and innovation, our vision is to compassionately contribute to solving cancer.

HBM Healthcare Investments AG

HBM Partners

Cormorant Asset Management

SR One

Wellington Management

Novartis Venture Fund

OrbiMed

Pontifax

Samsung Securities

Medicxi

3B Future Health Fund

SICAR

Windham Venture Partners

Fore Biotherapeutics

We are excited to be presenting a poster at #AACR24 next week:
Abstract #:4609 “Plixorafenib (plixo) synergizes with MEK inhibitors (MEKi) in MAPK pathway inhibition in BRAF V600 and non V600 alterations, with higher potency compared to early generation BRAFi and pan-RAFi”
https://lnkd.in/epDjVhJE
Members of the team, Drs Stacie Shepherd, Ted Everson, and Ping J., look forward to connecting with you there!

Today, FORE Bio named William R. Hinshaw as Chief Executive Officer. Bill’s extensive leadership experience in biotech and pharma companies, including the approvals of multiple oncology products and indications while at Novartis, will be key as FORE advances its ongoing Global Phase 2 FORTE study of plixorafenib.
Click here to read the full release https://lnkd.in/eaaZ7yfd

Today, FORE Bio announced that the Company will participate in the following investor conferences: 
·        Oppenheimer 34th Annual Healthcare Life Sciences Conference. The presentation will take place on Wednesday, February 14 from 8:00 a.m. – 8:30 a.m. ET.
·        Evercore ISI’s 2024 Emerging Private Biotech Conference. The presentation will take place on Wednesday, February 28 from 1:05 p.m. – 1:35 p.m. ET.
Please email Forebio@argotpartners.com to request a 1:1 meeting with management.

We wish our team and our partners around the world a very Happy Holiday season and a peaceful and prosperous New Year. #TeamFore

FORE Bio will be presenting at the 2023 RBC Capital Markets Private Company Conference on Thursday, December 14 at 8 a.m. ET. The company will also be hosting 1-on-1 meetings. Please email forebio@argotpartners.com to request a meeting.
https://lnkd.in/gST_nu7h

Metric
Company Name	Fore Bio
Symbol
MSH ID	BIO:FORE
Market	PRIVATE
Sector	9
Industry	Healthcare & Health Services
Country	US
Stage
Employee Count	39
Website	fore.bio
LinkedIn	forebiotherapeutics
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

BIO:FORE

Fore Bio

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue